Tumor-specific adenoviral gene therapy: Transcriptional repression of gene expression by utilizing p53-signal transduction pathways

Cancer Gene Therapy

Volumn 11, Issue 1, 2004, Pages 28-40

  Kühnel, Florian ^a   Zender, Lars ^a   Wirth, Thomas ^a   Schulte, Bernd ^a   Trautwein, Christian ^a   Manns, Michael ^a   Kubicka, Stefan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adenovirus; Chemotherapy; Gene therapy; p53; Regression; Tumor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; DOXORUBICIN; HYBRID PROTEIN; LUCIFERASE; PROTEIN; PROTEIN DBD; PROTEIN KRAB A; PROTEIN P53; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CELL MUTANT; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SILENCER GENE; TARGET CELL; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TRANSCRIPTION REPRESSION; TREATMENT INDICATION; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; NEOPLASMS; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0346725984     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700632     Document Type: Article

References (56)

1. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55: 5283-5287.
2. Cao G, Kuriyama S, Cui L, et al. Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy. Cancer Gene Ther. 1999;6:572-580.
3. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers [In Process Citation]. Cancer Res. 2000;60:5359-5364.
4. Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther. 2000;2:539-544.
5. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60: 334-341.
6. Ido A, Uto H, Moriuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 2001;61:3016-3021.
7. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001;8:1363-1371.
8. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene. 2001;20:7797-7803.
9. Ueda K, lwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61:6158-6162.
10. Lin T, Gu J, Zhang L, et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 2002;62:3620-3625.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
12. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
13. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607-614.
14. Ueda H, Ullrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet. 1995;9:41-47.
15. Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the GI arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996;16:2445-2452.
16. Steegenga WT, van Laar T, Riteco N, et al. Adenovirus E1A proteins inhibit activation of transcription by p53. Mol Cell Biol. 1996;16:2101-2109.
17. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 1991;67: 547-556.
18. Pengue G, Calabro V, Bartoli PC, Pagliuca A, Lania L. Repression of transcriptional activity at a distance by the evolutionarily conserved KRAB domain present in a subfamily of zinc finger proteins. Nucleic Acids Res. 1994;22:2908-2914.
19. Alland L, Muhle R, Hou Jr H, et al Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 1997;387:49-55.
20. Izzo MW, Strachan GD, Stubbs MC, Hall DJ. Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ. J Biol Chem. 1999;274: 19498-19506.
21. Denisenko ON, O'Neill B, Ostrowski J, Van SI, Bomsztyk K. Zik1, a transcriptional repressor that interacts with the heterogeneous nuclear ribonucleoprotein particle K protein. J Biol Chem. 1996;271:27701-27706.
22. Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 1996;12:2331-2342.
23. Bartholomew C, Kilbey A, Clark AM, Walker M. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene. 1997;14:569-577.
24. Galvin KM, Shi Y. Multiple mechanisms of transcriptional repression by YY1. Mol Cell Biol. 1997;17:3723-3732.
25. He GP, Kim S, Ro HS. Cloning and characterization of a novel zinc finger transcriptional repressor. A direct role of the zinc finger motif in repression. J Biol Chem. 1999;274:14678-14684.
26. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 1997;88:471-481.
27. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 1998;9:2577-2583.
28. Lichtsteiner S, Wuarin J, Schibler U. The interplay of DNA-binding proteins on the promoter of the mouse albumin gene. Cell. 1987;51:963-973.
29. Ghazal P, Lubon H, Hennighausen L. Specific interactions between transcription factors and the promoter-regulatory region of the human cytomegalovirus major immediate-early gene. J Virol. 1988;62:1076-1079.
30. Ghazal P, Lubon H, Hennighausen L. Multiple sequence-specific transcription factors modulate cytomegalovirus enhancer activity in vitro. Mol Cell Biol. 1988;8:1809-1811.
31. Baleja JD, Marmorstein R, Harrison SC, Wagner G. Solution structure of the DNA-binding domain of Cd2-GAL4 from S. cerevisiae. Nature. 1992;356:450-453.
32. Marmorstein R, Carey M, Ptashne M, Harrison SC. DNA recognition by GAL4: structure of a protein-DNA complex. Nature. 1992;356:408-414.
33. Liang SD, Marmorstein R, Harrison SC, Ptashine M. DNA sequence preferences of GAL4 and PPR1: how a subset of Zn2 Cys6 binuclear cluster proteins recognizes DNA. Mol Cell Biol. 1996;16:3773-3780.
34. Pengue G, Lania L. Kruppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements. Proc Natl Acad Sci USA. 1996;93:1015-1020.
35. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266: 807-810.
36. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-240.
37. Kubicka S, Claas C, Staab S, et al. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002;47:114-121.
38. Kubicka S, Kuhnel F, Zender L, et al. p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J Biol Chem. 1999;274:32137-32144.
39. Kuhnel F, Zender L, Paul Y, et al. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem. 2000;275:6421-6427.
40. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther. 2002;13:143-154.
41. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221-8229.
42. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998;58:5738-5748.
43. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol. 1999;73:9130-9136.
44. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 2000;74:6875-6884.
45. Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001;61:2953-2960.
46. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 2001;61:6377-6381.
47. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol. 2001;19:838-842.
48. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science. 1996;274:373-376.
49. Vollmer CM, Ribas A, Butterfield LH, et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 1999;59:4369-4374.
50. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]. Nat Med. 1998;4: 1068-1072.
51. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur HH. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72:9470-9478.
52. Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 2000;60:2666-2672.
53. Lipinski KS, Djeha AH, Krausz E, et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Ther. 2001;8:274-281.
54. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001;19:1035-1041.
55. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, Rauscher III FJ. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA. 1994;91:4509-4513.
56. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16:2549-2556.